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Comparison of quality of life in hepatitis B virus carriers versus
chronic hepatitis B virus carriers versus the normal population
Meltem IŞIKGÖZ TAŞBAKAN1, Özen ÖNEN SERTÖZ2, Hüsnü PULLUKÇU1,
Şebnem ÖZKÖREN ÇALIK1, Oğuz Reşat SİPAHİ1, Tansu YAMAZHAN1
Aim: To compare health related quality of life (HRQOL) in hepatitis B virus (HBV) carriers versus chronic HBV disease
carriers versus the normal population.
Materials and methods: The study sample consisted of 2 groups. HBV carriers were recruited from individuals who
were regularly followed-up at the Infectious Diseases and Clinical Microbiology outpatient clinic of our setting due to
inactivity in HBV infection. The control group was recruited from the same outpatient clinic among patients who had a
diagnosis of chronic HBV infection and who were not undergoing active treatment yet. Both groups were requested to
fill in the short form 36 questionnaire on HRQOL (HRQOL-SF-36) and a form to gather data about age, gender, and
education. We also compared the mean values of the SF-36 domain scores of these 2 groups with published scores of
healthy controls derived from the Turkish population.
Results: QOL in HBV carriers was greatly similar to that of patients with chronic HBV disease except for physical role
limitation scores and both HBV carriers and patients with chronic disease had lower HRQOL than the normal Turkish
population.
Conclusion: When compared with the normal Turkish population, QOL is affected negatively both in chronic HBV
infection patients and in HBV carriers.
Key words: Inactive hepatitis B infection, HRQOL-SF-36, Turkey

İnaktif hepatit B hastaları, kronik hepatit B hastaları ve sağlıklı populasyonunun
yaşam kalitelerinin karşılaştırılması
Amaç: Bu çalışmada, kliniğimizde ayaktan takip edilen inaktif hepatit B (HBV) enfeksiyonu olan hastalar ile kronik
hepatit B hastaları ve normal populasyonun yaşam kalitelerinin karşılaştırılması amaçlanmıştır.
Yöntem ve gereç: Çalışmaya alınacak hastalar iki gruba ayrılmıştır. İlk grubu Enfeksiyon Hastalıkları ve Klinik
Mikrobiyoloji kliniğine düzenli olarak gelen ve ayaktan takip edilen inaktif HBV hastaları oluşturmuştur. Kontrol
grubunda ise, aynı dönemde kronik HBV enfeksiyonu tanısı konulmuş ve henüz tedavi görmeyen hastalar yer almıştır.
Her iki grubun da yaş, cinsiyet ve eğitim derecesini sorgulayan bir anket formu ile yaşam kalitesini belirlemek üzere Kısa
Form 36 (SF-36) yaşam kalitesi ölçeğini doldurmaları istenmiştir. Bu iki gruptan elde edilen sonuçlar aynı zamanda
sağlıklı Türk populasyonunun yaşam kalitesi sonuçları ile karşılaştırılmıştır.
Bulgular: İnaktif hepatit B enfeksiyonu olan hastalar fiziksel rol güçlüğü skoru dışında kronik HBV hastaları ile büyük
oranda benzer bulunmuştur. Her iki grubun da yaşam kalitesi skorunun, normal Türk populasyonuna göre daha düşük
olduğu saptanmıştır.
Sonuç: Hem kronik HBV enfeksiyonu hem de inaktif HBV taşıyıcılarının yaşam kaliteleri normal populasyona göre
olumsuz etkilenmektedir.
Anahtar sözcükler: İnaktif Hepatit B enfeksiyonu, SF-36, Türkiye
Received: 26.07.2009 – Accepted: 11.01.2010
1
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University , Bornova, İzmir - TURKEY
2
Department of Psychiatry, Faculty of Medicine, Ege University , Bornova, İzmir - TURKEY
Correspondence: Meltem IŞIKGÖZ TAŞBAKAN, Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, Bornova, İzmir TURKEY
E-mail: tasbakan@yahoo.com

575

Quality of life in hepatitis B virus carriers

Introduction

Methods

Hepatitis B virus (HBV) infection is one of the
most important and widespread public health
problems in the world. Worldwide HBV is the main
cause of hepatitis in approximately 400 million people
and it causes 500,000-1,200,000 deaths per year. The
illness caused by HBV infection and its complications
are among the most common 3 causes of death in
Africa, Asia, and the Pacific coasts. The number of the
people exposed to HBV is about 2 billion worldwide
(1).

The current study was performed in the
Department of Infectious Diseases and Clinical
Microbiology and Department of Psychiatry, Faculty
of Medicine, Ege University, between January and
December 2006. The study sample consisted of 2
separate groups. The first group comprised HBV
carriers recruited from individuals who were regularly
followed-up in the Infectious Diseases and Clinical
Microbiology outpatient clinic due to inactive
hepatitis B virus infection (IHBV) [Low Hepatitis B
DNA levels (under 1 × 103 copies/mL, Robogene
Hepatitis B virus quantitation kit, Roboscreen,
Germany) and normal biochemical parameters
(Aspartate amino transferase-AST, alanine amino
transferase-ALT,
bilirubin,
no
human
immunodeficiency virus (HIV) or hepatitis C virus
infection and no drug abuse] (18,19).

In the world, the distribution of HBV infection
shows differences according to geographical regions.
Turkey is located in the moderate endemic region;
and according to the latest reports, there are
approximately 4 million HBV carriers in this country
(2).
As in all chronic diseases, these infections may
lead to psychological health problems. There are
numerous studies addressing the psychological wellbeing, psychosocial stressors related to the disease,
quality of life (QOL), and the effect of antiviral
treatments on QOL in patients with chronic hepatitis
(3-8). The recent studies concerning QOL of patients
with chronic viral hepatitis have found a relationship
between the QOL and the severity of the disease
(6,9,10) or interferon treatment (11,12). The data
about the effect of antiviral therapy on QOL are
inconclusive. In some studies, it was reported that
antiviral therapy reduced QOL (13-15), while some
others reported an improvement in the QOL after
successful antiviral therapy (5,16,17). In addition to
these findings, though some studies have reported
differences in terms of QOL in patients with chronic
viral hepatitis with respect to virus type (HBV or
hepatitis C virus-HCV) (3,10,12), some of them have
reported no significant differences (4,6).
This study aimed to evaluate the health related
quality of life (HRQOL) in HBV carriers and a control
group who had a diagnosis of chronic hepatitis B and
had not received any antiviral therapy yet and to
compare data of these 2 groups with the published
HRQOL of the normal Turkish population.
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All HBV carriers were informed about the study
and invited to participate on their control visits. The
second group was recruited from the same outpatient
clinic among patients who had a diagnosis of chronic
HBV infection [patients who had positive hepatitis B
surface antigen for at least 6 months, had hepatic
activity index ≥4 in liver biopsy, and whose HBV
DNA levels were above 1 × 104 copies/mL (Robogene
Hepatitis B virus quantitation kit, Roboscreen,
Germany) and AST and ALT levels at least 2-fold
higher than normal ranges] and who were not
undergoing active treatment yet. Patients who had
liver failure, cirrhosis, or another chronic disease, and
those that had received any antiviral or interferon
treatment were excluded from the study.
Questionnaire
Participants of the study were requested to fill in
the short-form 36 questionnaire on HRQOL
(HRQOL-SF-36). The questionnaire also included
information related to age, gender, marital status,
education, and work status.
The questionnaire comprised 36 items and 8
subscales/domains, including physical functioning
(PF), role limitations due to physical health problems
(RP), bodily pain (BP), general health perceptions
(GH), vitality (VT), social functioning (SF), role
limitations due to emotional problems (RE), and
mental health (MH). Each scale contained 2-10
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questions and was graded between 0 and 100 points
(14,20). The Turkish version of the SF-36 was
translated in 1999 and demonstrated good
psychometric properties (21).
Statistical analysis
Data were evaluated by SPSS 14.0. Descriptive
statistics such as frequencies were used to summarize
demographic characteristics of the study subjects.
Educational level of HBV carriers was significantly
higher than that of the patients with chronic HBV
infection. Therefore, we conducted analysis of
covariance (ANCOVA) and controlled educational
level as covariate in order to compare QOL between
the study groups. Pearson’s and Spearman’s correlation
coefficients were computed for each domain score
versus age, gender, and educational level. We
conducted logistic regression analysis to define the
most important factors in discriminating HBV
carriers from patients who had chronic HBV disease.
We also compared mean values of the SF-36 domain
scores of HBV carriers and patients who had chronic
HBV disease with the published scores for healthy
controls derived from the Turkish population (20) by
Student’s t test. A P value less than 0.05 was
considered significant.
Results
Demographics and the mean domain scores for
health related quality of life
Of the 131 HBV carriers, 128 (50 females, 78
males, mean age 41.42 ± 12.32, Table 1) agreed to
participate in the study. Their mean scores for

HRQOL were 86.05 ± 15.01, 77.15 ± 35.49, 79.43 ±
21.47, 61.82 ± 19.01, 67.89 ± 19.74, 79.29 ± 19.43,
76.04 ± 34.73, and 66.58 ± 16.89 in the PF, PH, BP,
GH, VT, SF, RE, and MH domains of the SF-36,
respectively (Table 2).
Of the 38 patients with chronic HBV diseases, 28
(9 males, 19 females, mean age 36.68 ± 10.56, Table 1)
agreed to participate in the study. The sociodemographic properties of the other 10 patients were
not different from those of the study participants.
Their mean scores for HRQOL were 80.7 ± 22.8, 54.4
± 37.3, 70.2 ± 22.2, 59.5 ± 22.7, 64.5 ± 22.7, 71.4 ±
27.6, 58.3 ± 42.2, and 65.8 ± 22.5 in the PF, PH, BP,
GH, VT, SF, RE, and MH domains of the SF-36,
respectively (Table 2).
The groups did not show any significant difference
in terms of age or gender, though a significant
difference was observed in educational level (Table 1).
The relationship between demographics and
QOL
We analyzed the relationship between gender, age,
and educational status versus QOL domains with
Spearman’s and Pearson’s correlation coefficients. We
found significant relationships between gender and
physical functioning (rs = –0.260, P = 0.001) and
between gender and bodily pain (rs = –0.232, P =
0.004). In terms of age, a significant relationship was
found only in role limitations due to physical health
problems (r = 0.164, P = 0.004). We also found
significant relationships between educational level
and role limitations due to physical health problems (r
= 0.219, P = 0.006) and between educational level and
bodily pain (r = 0.194, P = 0.02).

Table 1. Demographic characteristics of study participants.
Hepatitis B virus
carriers (n = 128)

Patients with chronic hepatitis
B virus disease (n = 28)

Statistical
analysis

Age (year)

41.42 (12.32)

36.68 (10.56)

F = 0.88
P = 0.06

Educational status year

12.38 (2.86)

10.82 (2.2)

F = 11.31
P = 0.002

Gender (n/%)
Female
Male

78 (60.9%)
50 (39.%)

9 (32.1%)
19 (67.9%)

X2 = 0.47
P = 0.49

Means (with standard deviations) and percentages
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Table 2. Comparison of quality of life between hepatitis B virus carriers and patients with chronic
hepatitis B virus disease not undergoing active treatment.
SF-36 domains

Hepatitis B virus
carriers n = 128

Chronic hepatitis B
virus infection n = 28

Covariance
analysis

Physical functioning

86.05 ± 15.01*

80.71 (22.8)

F = 1.55
df = 1.153
P = 0.22

Role limitation-Physical*

77.15 ± 35.49

54.46 (37.3)

F = 9.52
df = 1.153
P = 0.002

Bodily pain

79.43 ± 21.47*

70.25 (22.2)

F = 2.47
df = 1.153
P = 0.11

General health perception

61.82 ± 19.01*

59.59 (22.7)

F = 0.29
df = 1.153
P = 0.59

Vitality

67.89 ± 19.74

64.58 (22.7)

F = 0.29
df = 1.153
P = 0.59

Social functioning

79.29 ± 19.43*

71.42 (27.6)

F = 2.27
df = 1.153
P = 0.13

Role limitation-emotional

76.04 ±34.73*

58.33 (42.2)

F = 3.64
df = 1.153
P = 0.06

Mental health

66.58 ± 16.89*

65.85 (22.5)

F = 0.00
df = 1.153
P = 0.9

Means (with standard deviations), *P < 0.05

Comparison of the HBV carriers and patients
with chronic HBV disease in terms of HRQOL
We compared HRQOL between the groups by
testing the effect of educational level with ANCOVA.
The test revealed that there was only a statistically
significant difference in terms of role limitations due
to physical health problems between the study groups
(F = 9.52, df = 1.153, P = 0.002, Table 2). With regard
to the significant relationships between demographics
and some of the HRQOL domains, we performed
logistic regression analysis via forward selection to
identify the most important predicting factors in
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discriminating HBV carriers from patients with
chronic HBV disease. All variables (age, gender,
educational level, SF-36 domains) were entered into
the model. The test revealed that the role limitations
due to physical health problems domain of SF-36 (β =
–0.003, standard error = 0.001, t = –3.086, P = 0.002)
and educational level (β = –0.025, standard error =
0.011, t = –2.322, P = 0.022) were the most important
factors in discriminating groups from each other (F =
8.59, P < 0.001). The role limitations due to physical
health problems domain of SF-36 was first entered
into the model and explained 6.9% of the variance.
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The role limitations due to physical health problems
domain of SF-36 together with educational level
explained 10.1% of the variance.
Comparison of HRQOL life scores of the study
groups with published scores for healthy controls
derived from the Turkish population
When we compared HBV carriers’ domain scores
of SF-36 with Turkish population standards, HRQOL
of patients showed a profile similar to that of the
general Turkish population, with normal PF and VT
scores, but significantly lower RP, BP, GH, SF, RE, and
MH domain scores (Table 3, P < 0.001, P = 0.001, P <
0.001, P < 0.001, P < 0.001, P < 0.001, respectively).
Patients with chronic HBV disease not undergoing
active treatment showed a profile similar to that of
HBV carriers with respect to comparison with
Turkish population standards except in mental health
domain score.

Discussion
The most important finding of our study was that
the QOL profile in HBV carriers was greatly similar to
that of the patients with chronic HBV infection not
undergoing active treatment except in the role
limitations due to physical health problems domain
of SF-36.
HBV carriers showed better QOL than the patients
with chronic HBV disease in the RP domain of SF-36.
In addition, both HBV carriers and patients who
suffered from chronic HBV disease showed QOL
profiles greatly similar to those of the general Turkish
population standards except in the GH domain of SF36. Although there was not a significant difference
between HBV carriers and patients with chronic
disease in terms of the GH domain of SF-36, HBV
carriers obtained significantly lower scores from the
GH domain of SF-36 when compared with the general

Table 3. SF-36 scores of hepatitis B virus carriers and normal Turkish population.
Subscales of SF-36

Turkish population
standards

Hepatitis B virus
carriers (n = 128)

P value*

Physical functioning

86.6 ± 25.2

86.05 ± 15.01

*

t = –0.41
0.68

Role limitation-Physical

89.5 ± 29.6

77.15 ± 35.49

t = –3.63
P < 0.001

Bodily pain

86.1 ± 20.6

79.43 ± 21.47*

t = –3.51
P = 0.001

General health perception

73.9 ± 17.5

61.82 ± 19.01*

t = –7.19
P < 0.001

Vitality

67.0 ± 13.8

67.89 ± 19.74

t = –0.11
P = 0.92

Social functioning

94.8 ± 14.2

79.29 ± 19.43*

t = –8.84
P < 0.001

Role limitation-emotional

94.7 ± 20.9

76.04 ± 34.73*

t = –5.93
P < 0.001

Mental health

73.5± 11.6

66.58 ± 16.89*

t = –4.65
P < 0.001

*t test results
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Table 4. SF-36 scores of patients with hepatitis B virus disease not undergoing active treatment and
normal Turkish population.
Subscales of SF-36

Turkish population
standards

Patients with chronic hepatitis
b virus disease (n = 28)

P value*

Physical functioning

86.6 ± 25.2

80.71 ± 22.8

t = –1.37
P = 0.183

Role limitation-Physical

89.5 ± 29.6

54.46 ± 37.30

t = –4.97
P < 0.001

Bodily pain

86.1± 20.6

70.25 ± 22.23

t = –3.77
P = 0.001

General health perception

73.9 ± 17.5

59.58 ± 22.66

t = –3.34
P = 0.002

Vitality

67.0±13,8

64.59 ± 22.66

t = –0.56
P = 0.58

Social functioning

94.8±14.2

71.43 ± 27.61

t = –4.48
P < 0.001

Role limitation-emotional

94.7±20.9

58.33 ± 42.19

t = –4.56
P < 0.001

Mental health

73.5± 11.6

66.86 ± 22.51

t = –1.79
P = 0.08

*t test results

Turkish population standards, but the patients with
chronic disease did not.
HBV carriers are regarded as healthy individuals
and they are usually referred to as healthy carriers in
the literature. However, physicians want them to
arrange control visits regularly because there is usually
an obvious risk of becoming chronically ill at some
time in the future. Importance of giving extensive
information about the disease and the need for regular
control visits should be explained to the patients to
enhance QOL (10,22,23). In our outpatient clinic,
standard disease oriented information is given to all
patients.
Since QOL is a subjective concept, its definition
and measurement are rather difficult (24). In chronic
diseases, it is not possible to evaluate the clinical
course and the treatment success in a short time.
There are some universal factors affecting QOL such
as being a woman or being elderly (4). In the present
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study, we tested those factors by conducting
ANCOVA and logistic regression analysis. In
addition, there are numerous studies in the literature
addressing the effect of psychiatric morbidity on QOL
in patients with chronic viral liver diseases and these
studies reported that psychiatric morbidity affected
QOL negatively (25,26).
To our knowledge, there is no study concerning
the effect of psychiatric state on QOL in HBV carriers.
Only in one study were psychiatric disorders and
functioning evaluated in HBV carriers (7). According
to the study results, the authors reported that HBV
carriers had significantly higher levels of depression
and anxiety and lower level of functioning when
compared with healthy controls. They added that
worries about contamination and illnesses related to
HBV infection were associated with the presence of
psychiatric disorder. In the present study, as
mentioned above, the HBV carriers had lower scores
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in the RP, BP, GH, SF, RE, and MH domains of SF-36
when compared with the Turkish population
standards, and patients with chronic HBV disease not
undergoing active treatment showed a profile similar
to that of HBV carriers except in the MH domain
score. The reason that we did not come up with better
QOL in HBV carriers may be the fact that we did not
evaluate the psychiatric state of participants in the
current study. Therefore, an existing psychiatric
disease might have affected the results via its direct or
indirect effect on QOL (for example, an existing
anxiety might have caused misinformation about the
disease).
In this study, it was found that patients with
chronic HBV disease had worse QOL than carriers in
only the RP domain of SF-36. The RP domain of SF36 is included in the physical aspects of HRQOL. In
the literature, one of the reasons for impaired QOL
among patients with chronic hepatitis virus infections
was reported to be the effect of the disease itself
(22,27). With respect to the literature, we suggest that
the difference in QOL in terms of role limitations due
to physical health problems might have been affected
by the HBV disease itself via higher viral load or
higher serum liver enzymes than that of HBV carriers.
Although most of the HBV carriers do not have
any symptoms, it is possible to encounter one of the
non-specific symptoms such as weakness, fatigue,
vomiting, upper abdominal pain, or muscle and joint
pains in some of them. These symptoms may be the
cause of the decrease in the MH and RP domains of
SF-36 when compared with the healthy population.
HBV infection leads to cirrhosis in up to 20% of
those chronically infected and it is one of the most
common indicators for liver transplantation
worldwide (11). The disease, its long-term
complications, and its economic burden have a
significant impact on HRQOL. Although the
treatment of the chronic disease has several effects on
long-term survival, improvement in the QOL is also
necessary.
To our knowledge, this is the first study measuring
QOL in HBV carriers in Turkey. We chose the SF-36
health survey because its reliability and validity were
shown among different diseases and general
population groups (28). The SF-36 is a widely used

generic instrument and it has several other
advantages, including the measurement of high and
low scores and feasibility of a broad range of strategies
to be used in the interpretation of the results. Since
SF-36 is not specific to chronic HBV, the Chronic
Liver Disease Questionnaire (CLDQ) has been
developed. On the other hand, it is reported in a study
comparing the 2 questionnaires that SF-36 is as
effective as CLDQ and that CLDQ does not
contribute an extra important benefit (29).
Most of the studies about QOL related to chronic
viral hepatitis involve patients with HCV and studies
regarding QOL of the patients with HBV are
insufficient in the English literature. Foster et al.
reported a decrease in MH and GH scores in 30
English patients with HBV compared to healthy
volunteers (12). Pojoga et al. found lower QOL scores
for every domain of HRQOL (PF, RP, MH, RE, SF, VT,
and GH) in 66 Romanian patients (27 with HBV, 38
HCV, 1 HBV+HCV, 3 patients with HBV had high
transaminase levels) than the normal population (3).
Therefore, our study results with regard to
comparison of QOL of in HBV carriers and patients
with chronic HBV disease with the Turkish
population standards are consistent with the previous
study results reporting poor QOL in patients with
chronic liver disease when compared with the normal
population (3,4,30).
In this study, logistic regression analysis revealed
that the RP domain of SF-36 explained 6.9% of the
variance by itself while it accounted for 10.1% of the
variance together with the educational level. The
effect of the RP domain of SF-36 and educational level
in discriminating HBV carriers from patients with
chronic HBV disease may seem rather low but it
reflects our results. We think that if we had included
more variables in the study (for example, psychiatric
status), the results could have been different.
There are some limitations of our study. First, our
sample size with regard to patients with chronic HBV
disease was rather small and this might have affected
our results. Second, we did not control for the
psychiatric state. If we had included some psychiatric
measures depending on the existent literature, we
would probably have found psychiatric state to
decrease QOL.
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On the other hand, the importance of this study
was that it was the first to assess QOL in HBV carriers.
In addition, we invited all patients and healthy virus
carriers to participate in the current study in order
avoid selection bias.

Chronic HBV infection may require lifelong followup. Regular implementation of HRQOL
questionnaires may be helpful to physicians to apply
for psychiatric consultancy, when needed.

In conclusion, our study results suggest that the
QOL in HBV carriers is greatly similar to that of
patients with chronic HBV disease and both groups
have lower QOL than the normal Turkish population.
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